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Appendix 1 
Solutions 
0.05 % PBS-T 
  0.05% PBS (v/v), Tween-20 (Sigma) 
0.1 % PBS-T 
  0.1% PBS (v/v), Tween-20 (Sigma) 
12% separating gel (SDS PAGE) 
12% (w/v) acrylamide/bis-acrylamide (Sigma), 0.4 M Tris (pH 8.8), 0.1% (w/v) SDS, 
0.1% (w/v) ammonium persulfate (Sigma), 0.025% (w/v) TEMED (Sigma) 
5% stacking gel (SDS PAGE) 
12% (w/v) acrylamide/bis-acrylamide (Sigma), 0.13 M Tris (pH 6.8), 0.1% (w/v) SDS, 
0.1% (w/v) ammonium persulfate (Sigma), 0.1% (w/v) TEMED (Sigma) 
6 × Loading Dye (Agarose Gel Electrophoresis) 
  0.3% (w/v) bromophenol blue, 0.3% (w/v) xylene cyanol, 30% (v/v) glycerol 
Gill’s Haematoxylin 
0.2% (w/v) haematoxylin (monohydrate), 935 μM NaIO4, 26.4 mM Al2(SO4)3-18H2O, 
25% (v/v) ethylene glycol, 2% (v/v) glacial acetic acid 
PBS (phosphate-buffered saline) 
1.06 mM KH2PO4, 155.17 mM NaCl, 2.97mM Na2HPO4-7H2O, pH 7.4 
RIPA Buffer 
  PBS, 1% (w/v) NP-40, 5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS 148 
SDS-PAGE running buffer 
192 mM glycine, 25 mM Tris, 0.1% (w/v) SDS, pH 8.3 
SDS-PAGE sample buffer (2×) 
250 mM Tris (pH 6.8), 4% (w/v) SDS, 10% (v/v) glycerol, 2% (v/v) β-mercaptoethanol, 
0.006% (w/v) bromophenol blue 
TAE (Tris-acetate-EDTA) 
40 mM Tris-HCl, 20 mM acetic acid, 1 mM EDTA 
Trypan Blue 
0.4% (w/v) Trypan Blue (Sigma), 0.81% (w/v) NaCl, 0.06% (w/v) KH2PO4, pH 7.2 
Trypsin-EDTA 
0.25% (w/v) Trypsin, 0.53 mM EDTA-4Na 
Western transfer buffer 
25 mM Tris, 192 mM glycine, 20% (v/v) methanol, pH 8.3 
  149 
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Pg 29: Mention which parts of the protein are lacking in OPN B and  C due 













































EIA usually needs 5ug/ml Ab on bottom layer for optimal results; I used a 




































OPN C might be misfolded which could explain why Ab doesn’t bind in 
ELISA (poor conformation of the epitope). Could the missing part of OPN C 
(due to missing exon) cause misfolding?  Add the following ststement on pg 86 














OPN may not have been detected in mouse serum due to the serum 



























Pg 119: Claims of increased tumor vasculature in OPN expressing tumors 
should be supported by data (images) and be confirmed by CD31 staining. 
Claims about proliferation should be supported by ki67 and p21 stains. 










































Data is insufficient to label OPN as a biomarker, there are too many 
mentions of “biomarker”  and   The need to do blinded trials and measure 



















































































































Figure 1.16 The three splice variants of OPN. OPN-A represents the full length protein, whilst OPN-B and OPN-C each 
lack an exon (5 and 4 respectively). The lack of these exons results in the loss of either one serine phosphorylation site 
(PDPS) and a transglutaminase cross-linker (QKQ; exon 4) or two serine phosphorylation sites (SSEE; exon 5). GRGDS 
represents the signal sequence and RSK the thrombin cleavage site.






All cells Block-It transfected cells
Figure 4.15 Transfection of BLOCK-iTTM Fluorescent Oligo into Huh-7 and HeLa
cells allowed for the calculation of transfection efficiency of each cell line when using
the standard reverse transfection method of siRNA transfection. BLOCK-iTTM
Fluorescent Oligo emits its own fluorescent signal, and transfection efficiency was
calculated by visual calculation of fluorescent cells compared to total cells in a field of
view. Transfection with 8 nM BLOCK-iTTM gave less than 20% transfection efficiency
in both cell lines (data not shown). Transfection with both 20 nM and 40 nM gave
greater than 95% transfection in both cell lines.
HeLa 40nM Block-It
97% transfection efficiencyFigure 4.16 Sequence location of the three CD44 siRNA oligonucleotides received
from Invitrogen. siRNA 1 and 3 sequences bind within the constant (c) exons of CD44
and siRNA 2 binds at the junction between constant exons 1 and 2; therefore all siRNA
sequences should minimise expression of all CD44 isoforms (adapted from Liu and
Jiang 2006).